Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

Concomitant nevirapine impacts pharmacokinetic exposure to the antimalarial artemether-lumefantrine in African children.

<label>BACKGROUND</label>The antiretroviral drug nevirapine and the antimalarial artemisinin-based combination therapy artemether-lumefantrine are commonly co-administered to treat malaria in the context of HIV. Nevirapine is a known inhibitor of cytochrome P450 3A4, which metabolizes ar...

Full description

Bibliographic Details
Main Authors: Liusheng Huang, Vincent Carey, Jane C Lindsey, Florence Marzan, David Gingrich, Bobbie Graham, Linda Barlow-Mosha, Phionah K Ssemambo, Portia Kamthunzi, Sharon Nachman, Sunil Parikh, Francesca T Aweeka, IMPAACT P1079 protocol team
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2017-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC5655345?pdf=render

Internet

http://europepmc.org/articles/PMC5655345?pdf=render

Similar Items